Brief: Elicera Gives Update On Carma Study
May 22 (Reuters) - Elicera Therapeutics AB ELIC.ST: IN CARMA STUDY ELC-301 HAS SUCCESSFULLY CLEARED ALL ACTIVE LYMPHOMA IN TWO OUT OF THREE TREATED PATIENTS ON CARMA STUDY: COHORT 2 HAS ALREADY BEEN INITIATED Source text: ID:nWkr9PV2vM Further company coverage: ELIC.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application